The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
The first human glucagon-like peptide-1 analog (liraglutide) was registered in Russia in May 2010. This review contains data on the results of randomizedclinical studies of this preparation applied to the treatment of patients with DM2 as monotherapy and in combination with traditional hypoglycemica...
Enregistré dans:
Auteur principal: | Marina Vladimirovna Shestakova |
---|---|
Format: | article |
Langue: | EN RU |
Publié: |
Endocrinology Research Centre
2010
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/e55f297af3a34572a8a0d9d97b6af3d0 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
par: Gagik R. Galstyan, et autres
Publié: (2017) -
Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
par: Nina A. Petunina, et autres
Publié: (2018) -
First GLP-1 analog liraglutide: the result of clinical trails on efficacy
par: Alexander Sergeevich Ametov, et autres
Publié: (2011) -
The associations of incretin hormone concentration with gestational diabetes mellitus
par: Tatiana V. Saprina, et autres
Publié: (2016) -
Nephroprotective potential of glucagon-like peptide-1 receptor agonists
par: Minara S. Shamkhalova, et autres
Publié: (2020)